Transplant immunology最新文献

{"title":"Immunotherapy research in the Arab world: A bibliometric analysis","authors":"Ahmad Afyouni ,&nbsp;Jana Kotaich ,&nbsp;Sara Sarout ,&nbsp;Amarelle Chamoun ,&nbsp;Georgia Chkayban ,&nbsp;Saad El Hariri ,&nbsp;Tarek Baroud ,&nbsp;Adnan Fatfat ,&nbsp;Jad El Masri ,&nbsp;Pascale Salemeh","doi":"10.1016/j.trim.2025.102218","DOIUrl":"10.1016/j.trim.2025.102218","url":null,"abstract":"<div><h3>Background</h3><div>Immunotherapy is the concept of leveraging the immune system to treat diseases. Developing countries, including the Arab countries, have continued to lag in terms of biomedical research compared to other nations for several decades. Immunotherapy has been used in several fields, including cancer, transplantation, and vaccination. This article examined the activity and trend of immunotherapy research in the Arab world between 2000 and 2024.</div></div><div><h3>Methods</h3><div>The number of immunotherapy-related articles published by each Arab country, was assessed using the PubMed database between 2000 and 2024. Numbers were normalized with respect to each country's average population and average Gross Domestic Product (GDP).</div></div><div><h3>Results</h3><div>Arab countries contributed to 1.73 % of total immunotherapy papers. The number of immunotherapy publications has grown from 2000 to 2022, then decreased in the past 2 years. In terms of publications per million persons, Qatar ranked first (130.08 per million persons), while in terms of publications per national GDP, Lebanon ranked first (11.09 per billion US dollars). MeSH keywords VOSviewer showed a focus on vaccination, COVID-19, COVID-19 vaccines, and transplantation conditioning in the Arab world.</div></div><div><h3>Conclusions</h3><div>This bibliometric analysis provides insight into the actualities and trends of immunotherapy research in the Arab world. This offers a general background for scientists, clinicians, funders, and decision-makers. Addressing the barriers that face immunotherapy research remains a cornerstone in the plan to improve the Arab world's output and contribution to this field.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102218"},"PeriodicalIF":1.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys","authors":"Rosalia de Necochea Campion,&nbsp;Miguel Pesqueira,&nbsp;Paul Vallejos,&nbsp;Cameron McCullough,&nbsp;Alessio Bloesch,&nbsp;Steven P. LaRosa","doi":"10.1016/j.trim.2025.102215","DOIUrl":"10.1016/j.trim.2025.102215","url":null,"abstract":"<div><div>Kidney transplantation is considered the benchmark treatment for end-stage kidney disease patients, yet the scarcity of suitable kidneys poses a significant hindrance for patients and healthcare providers. One approach is to extend the criteria for the use of kidneys from deceased brain death and deceased circulatory death donors. Use of these organs, especially from these extended criteria donors, is associated with ischemia reperfusion injury and resultant delayed graft function as well as increased rates of allograft rejection. To lessen these complications as well as increase the time of organ viability assessment, machine perfusion has been evaluated on recovered kidneys. In this study we examined the immunogenic molecular content of perfusates from discarded organs that had undergone Controlled Oxygenated Rewarming (COR). Perfusates were analyzed for extracellular vesicles (EVs), DNA (Deoxyribonucleic acid), and microRNAs. These perfusates were then pumped over a plasma separator containing a lectin affinity resin. Following treatment, a significant diminution in extracellular vesicles, dsDNA (double-stranded DNA) associated with EVs, and microRNAs (miRNA) were observed. Specifically, in three out of the four renal perfusates analyzed there was significant removal of small EVs (&lt;200 nm) and vesicles loaded with dsDNA (<em>p</em> &lt; 0.05). Notably, depletion of larger EVs (100-500 nm) was found to be significant in all treated perfusates (<em>p</em> &lt; 0.01). NanoString analysis of miRNA found 5 species potentially involved in renal dysfunction (hsa-let 7a-5p, hsa-miR-148b-3p, hsa-miR-148a-3p, hsa-miR-29b-3pb and hsa-miR-99a5p) to be significantly depleted in treated renal perfusates (<em>p</em> ≤ 0.05). These results support a future study incorporating this treatment method into a dynamic machine perfusion circuit to explore if reduction of these mediators is associated with improved function of retrieved kidneys.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102215"},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic use of eculizumab for ABO-blood type incompatible kidney transplantation with extremely high ABO-blood type antibody titer: A two case report","authors":"Ayaka Mitomo ,&nbsp;Kazunari Tanabe ,&nbsp;Suguru Muraoka ,&nbsp;Mitsuru Yanai ,&nbsp;Sumi Hidaka ,&nbsp;Shuzo Kobayashi","doi":"10.1016/j.trim.2025.102213","DOIUrl":"10.1016/j.trim.2025.102213","url":null,"abstract":"<div><div>We report two cases of ABO-incompatible living-donor kidney transplantation (ABOi KT) performed in patients with exceptionally high ABO antibody titers. Both donor and recipient refused blood transfusions for religious reasons, limiting the use of plasma exchange. The desensitization protocol consisted of plasmapheresis (PP) using albumin solution, rituximab (300 mg), and high-dose intravenous immunoglobulin (IVIg; 4 g/kg). Despite aggressive desensitization procedure, ABO antibody titers did not go down to our acceptable upper limit of 1:64; the titer at transplantation was 1:256 in both cases. Given the high risk of acute antibody-mediated rejection (ABMR), the anti-complement C5 component monoclonal antibody (eculizumab; 900 mg) was administered prophylactically before graft reperfusion in order to inhibit complement activation. For both cases, postoperative courses were unremarkable, without any rejection episodes over one year. No additional doses of eculizumab were administered post-transplantation. We suggest that ABOi KT may be considered safe once early post-transplant ABMR is suppressed, allowing for immunological accommodation. Furthermore, despite the elevated antibody titers, the prophylaxis with eculizumab successfully inhibited early post-transplant complement activation, protecting kidney transplants from ABMR. These findings support the prophylactic use of eculizumab administration at the time of transplantation in high-risk cases of ABOi KT.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102213"},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of anti-HLA antibodies screening techniques on waiting time on the waiting list and kidney transplant outcomes","authors":"Juan López-Pérez ,&nbsp;Florentino Villanego ,&nbsp;Auxiliadora Mazuecos ,&nbsp;Antonio Nieto","doi":"10.1016/j.trim.2025.102214","DOIUrl":"10.1016/j.trim.2025.102214","url":null,"abstract":"<div><h3>Background</h3><div>Differences in sensitivity and specificity between the techniques used for the detection of anti-HLA antibodies before kidney transplantation (KT) can lead to contradictory results that influence patients' management. Our aim is to analyse whether the technique used, based on complement-mediated-cytotoxicity (CDC) or on microsphere fluorimetry (xMAP), conditions the waiting time until transplantation and its results.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of the KT performed in our centre from 2006 to 2018 whose pre-transplant anti-HLA specificity determination and definition of prohibited antigens was performed by CDC (2006–2011) or by xMAP (2012–2018). Living donor KT recipients were excluded. The influence of each technique on the time on the waiting list and on the outcome of kidney transplantation was analysed, using as indicators the initial function of the graft, the rate of humoral rejection and graft survival.</div></div><div><h3>Results</h3><div>During the period of the study, 622 patients were included (264 were studied by CDC and 358 by xMAP). Recipient and donor age was higher in the xMAP group (<em>p</em> &lt; 0.001). Additionally, most sensitised patients were in the xMAP group (p &lt; 0.001). However, they received a KT earlier. There were no differences in the rate of acute humoral rejection between groups. Nevertheless, graft survival was better in the xMAP group.</div></div><div><h3>Conclusions</h3><div>The introduction of the xMAP technique in our centre has meant an improvement in terms of accessibility to transplantation and the initial management of the patient. However, it does not ameliorate the indicators of graft rejection.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102214"},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-transplant and transplant parameters predict long-term survival after hematopoietic cell transplantation using machine learning","authors":"Panagiotis G. Asteris ,&nbsp;Amir H. Gandomi ,&nbsp;Danial J. Armaghani ,&nbsp;Ahmed Salih Mohammed ,&nbsp;Zoi Bousiou ,&nbsp;Ioannis Batsis ,&nbsp;Nikolaos Spyridis ,&nbsp;Georgios Karavalakis ,&nbsp;Anna Vardi ,&nbsp;Leonidas Triantafyllidis ,&nbsp;Evangelos I. Koutras ,&nbsp;Nikos Zygouris ,&nbsp;Georgios A. Drosopoulos ,&nbsp;Nikolaos A. Fountas ,&nbsp;Nikolaos M. Vaxevanidis ,&nbsp;Abidhan Bardhan ,&nbsp;Pijush Samui ,&nbsp;George D. Hatzigeorgiou ,&nbsp;Jian Zhou ,&nbsp;Konstantina V. Leontari ,&nbsp;Eleni Gavriilaki","doi":"10.1016/j.trim.2025.102211","DOIUrl":"10.1016/j.trim.2025.102211","url":null,"abstract":"<div><h3>Background</h3><div>Allogeneic hematopoietic stem transplantation (allo-HSCT) constitutes a curative treatment for various hematological malignancies. However, various complications limit the therapeutic efficacy of this approach, increasing the morbidity and decreasing the overall survival of allo-HSCT recipients. In everyday clinical practice, various laboratory and clinical biomarkers and scorning systems have been developed and implemented focusing on the recognition of high-risk patients for organ dysfunction-related complications and those who might experience low overall survival. However, the predictive accuracy of developed scores has been reported deficient in some studies. The aim of the current retrospective study is to develop a machine learning (ML) model to predict the long-term survivorship of patients who receive allo-HSCT based on clinical pre- and post-allo-HSCT variables, and on transplantation-related characteristics.</div></div><div><h3>Methods</h3><div>For this purpose, a database of 564 allo-HSCT recipients incorporating 16 clinical and laboratory variables and the survivorship status of the patients during follow-up (Alive, Dead, Alive but follow-up less than 24 months) was used. An ML model was developed and tested, based on the previously published Data Ensemble Refinement Greedy Algorithm (DEGRA) algorithm.</div></div><div><h3>Results</h3><div>A predictive ML model was built with 92.02 % accuracy. The eight parameters included in the algorithm were the following: CD34+ cells infused, patients' age and gender, conditioning regimen toxicity, disease risk index (DRI), graft source, and platelet and neutrophil engraftment.</div></div><div><h3>Conclusion</h3><div>To our knowledge, this is the first AI model incorporating post-HSCT variables for the prediction of mortality in adult HSCT recipients. In the era of precision medicine, the recognition of patients who undergo allo-HSCT and face a great risk for mortality and morbidity, with high-accuracy algorithms is crucial.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102211"},"PeriodicalIF":1.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JC polyomavirus-associated nephropathy in a kidney allograft: A case report and literature review","authors":"Xue Li ,&nbsp;Wei Wang ,&nbsp;Jing Jiang ,&nbsp;Dongrui Cheng ,&nbsp;Jinsong Chen","doi":"10.1016/j.trim.2025.102212","DOIUrl":"10.1016/j.trim.2025.102212","url":null,"abstract":"<div><div>JC virus-associated nephropathy (JCV PyVAN) is a late infectious complication after kidney transplantation and represents a rare cause of allograft dysfunction. Herein, we report a case of JCV PyVAN in a 34-year-old woman presenting with elevated serum creatinine 13 years after kidney transplantation. Diagnosis was rendered with a positive JC viremia and viruria, in combination with histological findings consistent with PyVAN and immunohistochemical staining for large T antigen SV-40. A total of 17 cases of JCV PyVAN were retrieved from the reported literature, and patient characteristics, treatments and prognosis were summarized. This study highlights that although the prognosis for JCV PyVAN is generally favorable with reduction of immunosuppression, future research should further investigate the optimal therapeutic management of this rare condition.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102212"},"PeriodicalIF":1.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of anti-donor CD8 alloimmune response in clinically diagnosed acute rejection early after living-donor lobar lung transplantation and its impact on outcome","authors":"Satona Tanaka ,&nbsp;Naoki Tanimine ,&nbsp;Akiyoshi Nakakura ,&nbsp;Koichiro Uchida ,&nbsp;Ichiro Sakanoue ,&nbsp;Hidenao Kayawake ,&nbsp;Mamoru Takahashi ,&nbsp;Shigeto Nishikawa ,&nbsp;Yojiro Yutaka ,&nbsp;Yoshito Yamada ,&nbsp;Akihiro Ohsumi ,&nbsp;Masatsugu Hamaji ,&nbsp;Daisuke Nakajima ,&nbsp;Toyofumi F. Chen-Yoshikawa ,&nbsp;Yuka Tanaka ,&nbsp;Hideki Ohdan ,&nbsp;Hiroshi Date","doi":"10.1016/j.trim.2025.102201","DOIUrl":"10.1016/j.trim.2025.102201","url":null,"abstract":"<div><h3>Background</h3><div>The characteristics and prognostic impacts of early graft infiltration after lung transplantation and clinically diagnosed acute rejection remain unclear. Furthermore, the alloimmune response status in lung transplantation remains uninvestigated.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we evaluated 92 living-donor lobar lung transplantations (LDLLT) to establish the effect of graft infiltration—diagnosed as acute rejection—within one-month post-transplantation (cAR), on chronic lung allograft dysfunction (CLAD)-free LDLLT survival. The alloimmune response was evaluated using the carboxyfluorescein diacetate succinimidyl ester (CFSE)-mixed lymphocyte reaction (MLR) in lymphocytes isolated from donor and recipient blood one week after LDLLT. The anti-donor proliferation of CD4+ and CD8+ T cells was determined using flow cytometry.</div></div><div><h3>Results</h3><div>cAR was observed in 54 (58.7 %) patients who underwent LDLLT. The median postoperative day of cAR occurrence was 7 days (ranging between 5 and 28 days). Only one episode of cAR occurred in 51 patients (94.4 %). CLAD-free survival was significantly lower in patients who underwent cAR, especially within 2 years after LDLLT (<em>p</em> = 0.016). Thirteen CFSE-MLR assays were performed in seven consecutive LDLLT cases (six bilateral and one unilateral LDLLT). Increased anti-donor proliferation of CD8+ T cells, but not CD4+ T cells, was associated with cAR, irrespective of human leukocyte antigen (HLA) class I mismatch.</div></div><div><h3>Conclusion</h3><div>Early lung graft infiltration after LDLLT increases the risk of the early development of CALD. Augmented anti-donor CD8 + response was also associated with graft infiltration, which could not be predicted from HLA mismatches but could be monitored using MLR in LDLLT.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102201"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Despite routing to GI and pulmonary tissues, donor cells fail to engraft after intra-amniotic or intravascular cell delivery in a healthy allogeneic mouse model","authors":"Kerry A. Swanson,&nbsp;Hannah M. Phelps,&nbsp;Matthew T. Grant,&nbsp;Eliza P. Lang,&nbsp;Brad W. Warner,&nbsp;Jesse D. Vrecenak","doi":"10.1016/j.trim.2025.102200","DOIUrl":"10.1016/j.trim.2025.102200","url":null,"abstract":"<div><div>In utero hematopoietic cell transplantation (IUHCT) exploits tolerogenic fetal immunologic development to facilitate engraftment of donor. Non-hematopoietic donor-derived cells have been described in both in-utero and post-natal models of hematopoietic cell transplantation. However, while epithelial routing has been reported, long-term engraftment following IUHCT has not been well studied. We utilized intra-amniotic (IA) or intravascular (IV) IUHCT to evaluate routing and engraftment within the pulmonary and gastrointestinal (GI) tract. High donor-cell viability is observed in the amniotic fluid 24 h after IA injection (mean 89.1 %). At 24 and 72 h, donor cells were present within the lumens of GI and pulmonary tissues and in the parenchyma of the liver, suggesting that donor cells route effectively to epithelial surfaces and hematogenous targets following IA injection. However, following IA delivery, long-term engraftment was not observed in peripheral blood, and there was no evidence of donor-derived cells in any target tissue including lung, bowel, or liver. Following IV injection, mean peripheral blood chimerism at terminal harvest was 23.86 % (SEM 12.44; Range 0.00–98.90). Following IV delivery, donor-derived cells were noted in the bowel, liver, and lung but not in the epithelium, suggesting these cells are circulating or tissue-resident leukocytes. Despite the routing of donor cells to multiple fetal sites, the IA injection was an extremely inefficient method for long-term engraftment in the hematopoietic niche, in organ parenchyma, or on epithelial surfaces. In contrast, despite IV IUHCT being able to consistently produce hematopoietic engraftment, epithelial engraftment was not observed, suggesting a limited role for IV IHUCT in epithelial disorders.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102200"},"PeriodicalIF":1.6,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-HLA antibodies may be a subset of polyreactive immunoglobulins generated after viral superinfection","authors":"Steven D. Heron ,&nbsp;Jim Shaw ,&nbsp;Johannes Dapprich","doi":"10.1016/j.trim.2025.102197","DOIUrl":"10.1016/j.trim.2025.102197","url":null,"abstract":"<div><div>Chronic rejection remains an obstacle to long-term allograft survival. Donor-specific anti-HLA antibodies (DSA) play a significant role in causing chronic antibody-mediated allograft rejection. Exposure to mismatched HLA antigens via transfusion, pregnancy, or transplanted tissue has been described in the literature as an immunogenic stimulus of anti-HLA antibodies. Yet anti-HLA antibodies also develop in the absence of traditional sensitization events and molecular mimicry has been postulated as a stimulus for these naturally occurring alloantibodies. While heterologous reactivity has been documented between virus components and allogeneic T cells, there is insufficient evidence to support the development of anti-HLA antibodies from viral components. We hypothesized that anti-HLA antibodies may develop following viral coinfection or superinfection. The objectives of this investigation included: 1) developing an in-silico algorithm to identify viral peptide components that exhibit HLA-specific homology, and 2) identifying cellular changes that take place during ischemia/reperfusion injury which could facilitate the generation of novel anti-HLA antibodies from viral sources. We developed the neoepitope transplant rejection and autoimmune disease (NETRAD) algorithm to identify amino acid sequence homology between viral envelope proteins and HLA. The algorithm integrates post-translational protein modifications that are consistent with ischemia/reperfusion injury. Seventy-two HLA-specific epitopes were demarcated as examples using this approach. In conclusion, we present in-silico evidence which supports the identification of anti-HLA antibodies as a subset of polyreactive antibodies generated from stress-modified viral envelope proteins. Remarkably, each targeted HLA epitope associated with a distinct anti-HLA antibody could be consistently attributed to a major envelope glycoprotein component of Epstein Barr virus.</div><div><strong>Transplant Immunology manuscript</strong> # TRIM-D-24-00351.</div><div><strong>Dryad data repository:</strong> <span><span>https://doi.org/10.5061/dryad.qjq2bvqpq</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"90 ","pages":"Article 102197"},"PeriodicalIF":1.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) in pediatrics: A systematic review","authors":"Mohammad Hassan Sohouli ,&nbsp;Arefeh Zahmatkesh ,&nbsp;Zahid Khan ,&nbsp;Maryam Behfar ,&nbsp;Amir Ali Hamidieh ,&nbsp;Pejman Rohani","doi":"10.1016/j.trim.2025.102199","DOIUrl":"10.1016/j.trim.2025.102199","url":null,"abstract":"<div><h3>Background</h3><div>Allogeneic hematopoietic stem cell transplantation (HSCT) provides children with life-threatening conditions an opportunity for survival. Complications from graft-versus-host disease (GVHD) are a major source of morbidity and death, recently linked to gut dysbiosis in the hematopoietic stem cell transplantation (HSCT) population. But so far, no comprehensive study has been conducted to investigate this relationship in the children population. In this systematic study, we investigated the Gut microbiota variation and diversity and gut GVHD in pediatrics.</div></div><div><h3>Methods</h3><div>A systematic review according to PRISMA standards was performed from inception till August 2024. Out of 568 originally chosen publications, 10 studies involving 490 pediatric subjects satisfied the eligibility criteria and were included.</div></div><div><h3>Results</h3><div>The findings obtained from the study included in the present systematic study mostly indicated the use of combined treatments including Busulfan, Cyclophosphamide, and total body irradiation and in some studies the use of anti-thymocyte globulin and Melphalan as conditioning regimens. In addition, out of 10 reviewed studies, 9 reported a significant decrease in gut microbiota diversity following GVHD. However, in all studies, an increased variation was reported. So that most of the studies showed a decrease in the levels of beneficial bacteria and producers of short-chain fatty acid products in the intestine such as <em>Ruminococcaceae</em> and <em>Enterococcus</em>, which is also observed in the intestinal microbiota population of healthy people.</div></div><div><h3>Conclusion</h3><div>As a result, our findings indicated a decrease in diversity as well as a change in intestinal microbiota in children with GVHD under HSCT in most of the studies.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102199"},"PeriodicalIF":1.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}